Patient- and physician-related risk factors for hyperkalaemia in potassium-increasing drug-drug interactions
Emmanuel Eschmann, Patrick E Beeler, Vladimir Kaplan, Markus Schneemann, Gregor Zünd, Jürg Blaser, Emmanuel Eschmann, Patrick E Beeler, Vladimir Kaplan, Markus Schneemann, Gregor Zünd, Jürg Blaser
Abstract
Purpose: Hyperkalaemia due to potassium-increasing drug-drug interactions (DDIs) is a clinically important adverse drug event. The purpose of this study was to identify patient- and physician-related risk factors for the development of hyperkalaemia.
Methods: The risk for adult patients hospitalised in the University Hospital Zurich between 1 December 2009 and 31 December 2011 of developing hyperkalaemia was correlated with patient characteristics, number, type and duration of potassium-increasing DDIs and frequency of serum potassium monitoring.
Results: The 76,467 patients included in this study were prescribed 8,413 potentially severe potassium-increasing DDIs. Patient-related characteristics associated with the development of hyperkalaemia were pulmonary allograft [relative risk (RR) 5.1; p < 0.0001), impaired renal function (RR 2.7; p < 0.0001), diabetes mellitus (RR 1.6; p = 0.002) and female gender (RR 1.5; p = 0.007). Risk factors associated with medication were number of concurrently administered potassium-increasing drugs (RR 3.3 per additional drug; p < 0.0001) and longer duration of the DDI (RR 4.9 for duration ≥6 days; p < 0.0001). Physician-related factors associated with the development of hyperkalaemia were undetermined or elevated serum potassium level before treatment initiation (RR 2.2; p < 0.001) and infrequent monitoring of serum potassium during a DDI (interval >48 h: RR 1.6; p < 0.01).
Conclusion: Strategies for reducing the risk of hyperkalaemia during potassium-increasing DDIs should consider both patient- and physician-related risk factors.
References
- Respiration. 2012;84(2):163-75
- Arch Intern Med. 2008 Sep 22;168(17):1890-6
- Rev Pneumol Clin. 2010 Feb;67(1):28-49
- Drug Saf. 2013 Jun;36(6):427-34
- Pharmacology. 2009;84(6):333-9
- J Am Pharm Assoc (2003). 2004 Mar-Apr;44(2):136-41
- Am J Cardiol. 2012 Mar 1;109(5):693-8
- Eur J Clin Pharmacol. 2013 Jan;69(1):97-110
- Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266
- J Gen Intern Med. 2010 Apr;25(4):326-33
- Br J Clin Pharmacol. 2009 Aug;68(2):187-93
- Crit Care Clin. 2002 Apr;18(2):273-88, vi
- Eur J Clin Chem Clin Biochem. 1992 Dec;30(12):881-99
- Int J Clin Pharmacol Biopharm. 1976 Apr;13(3):187-95
- N Engl J Med. 2004 Aug 5;351(6):543-51
- Ann Pharmacother. 2010 Mar;44(3):466-70
- J Manag Care Pharm. 2006 Jun;12(5):383-9
- Eur J Clin Pharmacol. 2010 Dec;66(12):1257-64
- Expert Opin Drug Saf. 2011 Nov;10(6):871-82
- Drug Saf. 2007;30(1):71-80
- J Am Pharm Assoc (Wash). 2001 Mar-Apr;41(2):161-5
- Medicine (Baltimore). 1985 Nov;64(6):357-70
- J Diabet Complications. 1990 Jan-Mar;4(1):3-7
- Pharmacotherapy. 1998 Sep-Oct;18(5):1112-20
- J Am Med Inform Assoc. 2006 Mar-Apr;13(2):138-47
- Pharmacoepidemiol Drug Saf. 2010 Mar;19(3):266-72
- Nephrol Dial Transplant. 2008 Dec;23(12):3939-45
- Nephron. 1976;16(1):31-41
- Swiss Med Wkly. 2012 Feb 10;142:w13522
- Eur J Clin Pharmacol. 2011 Sep;67(9):933-40
- Ann Pharmacother. 2010 Jan;44(1):28-34
Source: PubMed